Regulatory Signals
Tebentafusp (IMCgp100) significantly improved overall survival in HLA-A*02:01-positive advanced uveal melanoma, establishing it as a first-line treatment. Read more
The European Commission has approved ENFLONSIA (clesrovimab) as the first RSV preventive option for infants in the EU. Read more
The FDA has accepted Roche's sBLA for Gazyva/Gazyvaro, based on phase III ALLEGORY data showing significant efficacy in SLE. Read more
Clinical Catalysts
The Phase III METEOROID study demonstrated that ENSPRYNG (satralizumab) reduced the risk of relapses by 68% in MOGAD patients. Read more
The seven-year analysis of the CROWN trial shows a 55% likelihood of remaining alive without disease progression for patients treated with LORBRENA, with median progression-free s… Read more
MAGED4 is upregulated in hepatocellular carcinoma and promotes tumor progression by activating the JAK2/STAT3 pathway. Read more
Competitive Intelligence
The positive Phase 3 results for pirtobrutinib in combination with other therapies could significantly enhance Lilly's competitive positioning in the hematology market. This devel… Read more
The Pra-ffd hydrogel demonstrated improved bioavailability and reduced ocular inflammation in preclinical models. Read more
A Phase 3 study is underway to evaluate the efficacy and safety of BLU-5937 in adults with refractory chronic cough. Read more
Read full intelligence at humanexasignals.com